Physician profile
Fatima E Khan
NPI 1891037446
$10,039.33
in general payments reported to CMS, 2019-2025
33 companies · $3,145 in 2025
The $3,145 reported for 2025 was more than what 77% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $42.53 · 2021: $425 · 2022: $1,656 · 2023: $2,419 · 2024: $2,230 · 2025: $3,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,354 · Education: $390 · Consulting Fee: $50.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,353.62 |
| Education | $389.95 |
| Consulting Fee | $50.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,400.69 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,681.15 | 2020-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $1,088.91 | 2019-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $854.60 | 2022-2025 | Dupixent |
| Genentech USA, INC. | $541.12 | 2021-2025 | Xolair |
| Csl Behring | $490.99 | 2022-2025 | Hizentra, Haegarda, Andembry |
| Pfizer INC. | $383.03 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $331.87 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $274.44 | 2021-2025 | Hyqvia, Cuvitru, Takhzyro |
| Amgen INC. | $238.56 | 2021-2025 | Tezspire |
| Insmed, INC. | $168.22 | 2025 | Brinsupri, Arikayce |
| Novartis Pharmaceuticals Corporation | $164.74 | 2022-2025 | |
| Leo Pharma INC. | $164.44 | 2022-2025 | Anzupgo |
| Biocryst US Sales Co., LLC | $153.36 | 2021-2025 | Orladeyo |
| Lilly USA, LLC | $150.42 | 2024 | Ebglyss |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $128.23 | 2021-2024 | Ruconest |
| Arcutis Biotherapeutics, INC. | $107.66 | 2025 | Zoryve |
| Abbvie INC. | $83.11 | 2021-2023 | |
| Phadia US INC. | $75.24 | 2022-2023 | Immunocap |
| Teva Pharmaceuticals USA, INC. | $71.54 | 2021-2022 | |
| Octapharma USA, INC. | $70.38 | 2021 | |
| Optinose US, INC. | $67.00 | 2022-2024 | |
| Covis Pharma Gmbh | $57.46 | 2022-2023 | |
| Adma Biomanufacturing LLC | $50.72 | 2023-2025 | |
| Grifols USA, LLC | $41.13 | 2022 | |
| Blueprint Medicines Corporation | $32.10 | 2025 | Ayvakit |
| Hikma Pharmaceuticals USA | $32.07 | 2023 | Ryaltris |
| Galderma Laboratories, L.P. | $29.25 | 2025 | Nemluvio |
| Avadel Cns Pharmaceuticals, LLC | $27.17 | 2025 | Lumryz |
| Harmony Biosciences LLC | $24.33 | 2025 | |
| Azurity Pharmaceuticals, INC. | $21.26 | 2025 | Alvesco |
| Aimmune Therapeutics, INC. | $19.87 | 2022 | |
| Gc Biopharma USA, INC. | $14.27 | 2025 | Alyglo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fatima Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.